Bioverativ

This page shows the latest Bioverativ news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets EU OK for Ablynx flagship drug Cablivi

of Bioverativ earlier this year which added two marketed haemophilia drugs as well as a pipeline of blood disorder products including genome editing drugs and gene therapies.

Latest news

Dupixent bounce-back helps stem diabetes declines at Sanofi

A bright point was the rare blood disorder business bolted on with the $11.6bn acquisition of Bioverativ, up 15.5% on a pro forma basis to 257m, and Sanofi is
Sanofi poaches Peugeot's finance head

However it has made some promising new acquisitions this year, including haemophilia and blood disorder specialists Bioverativ, which it bought for $11.6bn.
Evotec says Sanofi deal makes it anti-infectives powerhouse

revamp of its pipeline following the acquisitions of Ablynx and Bioverativ.
BioMarin ups the ante for pivotal haemophilia gene therapy trial

In the chase are Spark Therapeutics’SPK-8011, Pfizer/Sangamo Biosciences’SB-525 and Shire’s SHP654 - all in phase I/II testing - with uniQure and Sanofi’s Bioverativ unit also
Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group. ... Furthermore, with the consolidation of Bioverativ and the acquisition of

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Biogen's spin-out, Bioverativ, had not even got past its first anniversary as a Nasdaq-listed company before being snapped up by Sanofi for $11.6bn (although this is not ... Paying $105 per share in cash (64% premium over Bioverativ’s closing price on

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Industry appointments

Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... The firm has managed to poach Bioverativ’s senior executive Rogerio Vivaldi (pictured
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer

the chief executive officer and president of Syntonix Pharmaceuticals - a wholly owned subsidiary of Biogen, now Bioverativ - and vice president of global operations.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Sudler London - Senior Medical Writer: Competitive

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Systematic Review Lead- London: Negotiable

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Manager- 4 days per week or full-time: Salary TBC

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Market Access Consultant - Greater Manchester: Negotiable

Senior Writer, Healthcare Advertising, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer: Salary is DOE

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Account Director or Senior Account Director: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Healthcare PR Director: £100, 000 – £120, 000 benefits

Sudler London - Account Director: Competitive

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director, Healthcare Advertising Agency: Salary TBC

Associate Scientific Director: Salary TBC

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Subscribe to our email news alerts

PMHub

Add my company

Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....